Our tax specialists will highlight the past year, review the impact of the Affordable Care Act (ACA) on employers in 2014 and beyond, review developments in information reporting, provide an outlook of potential future initiatives from the Internal Revenue Service, and other issues impacting healthcare providers, universities and other tax-exempt organizations.
The third quarter of 2013 realized a slight uptick over the prior two quarters in the volume of healthcare services deals with 138 total transactions. However, the value of the dealsannounced in Q3 2013, $15.8 billion, was up 35% over the second quarter. In both volume and value, the year-to-date period for 2013 continues to lag the same period in 2012 with volume down 4.6% and value down 25%.
This publication highlights factors the industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.
As patients exert greater control over their healthcare, drug makers need to master the complexities of consumer behavior to demonstrate value in the new health economy. Consumers are willing to offer feedback that informs who they are, how they behave and how existing biases impact their behavior. Drug makers that tap into this feedback will reach a new level of success.
Pharmaceutical and Life Sciences - 2013 SEC comment letter trend compiles and analyzes the SEC staff’s comment letters issued over the past few years to registrants across different sectors within the Pharmaceutical and Life Sciences industry and provides highlights surrounding current hot topics and sample comments.
HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders. In this issue of HR Innovation, we focus on the continually changing HR landscape and what organizations need to do to take control of today’s opportunities and tomorrow’s decisions.
This installment of PwC's Healthcare, Higher Education and Not-for-Profit quarterly webcast series covers FASB standard setting developments that have occurred since our July webcast. As always, the focus is on not-for-profit organizations that apply FASB standards, with an emphasis on healthcare and higher education institutions.
Watch this complimentary webcast where we present the findings from PwC's Health Research Institute's (HRI) new report: Medtech companies prepare for an innovation makeover. This webcast discusses leading industry practices that result in high impact innovation strategies designed to drive business models, management processes and product development efforts.
The mere concept of innovation needs redefining in a health ecosystem that demands and rewards new models for delivering better care across a broader patient population at lower costs. Medtech companies must get ready to compete in this new environment or risk being displaced by ones that can show evidence their innovations achieve the same high clinical standards but are faster, better, cheaper, and more integrated into the care delivery continuum.
This publication highlights factors the medical technology industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.
Q2 2013 continues the trends started in late 2012 and in Q1 2013 with both financial and strategic buyers exhibiting cautious behaviors across all sectors. Through Q2 2013, health services deal volume has increased 3.9% from 127 deals in Q1 2013 to 132 deals in Q2 2013. The value of these transactions has also increased 151% across the same periods.
Please watch a complimentary webcast featuring Virginia Herold from California Board of Pharmacy and Siobhan O'Bara from GS1 US as featured speakers who provide their perspectives on serialization and ePedigree regulations, and the industry's current state of readiness. PwC provides a brief overview on its approach for helping manufacturers, distributors, and pharmacies.
As healthcare systems face increasing challenges related to implementation of the Affordable Care Act, talent will be a large focus to keep expenditures low and productivity high. HR will need to work to engage and retain their key employees – high performers and those within pivotal roles – to help brace for these changes.
Pharmaceutical companies stand ready to be tested in a world where a drug’s success is more closely tied to its performance. The challenges mount with competition from generics and growing pressure to reduce costs. Now, insurers and integrated providers are driven by models that reward health outcomes and cost savings. For success, drug makers are exploring real-world evidence, new payment models, and the right partnerships.
The next installment in PwC's Healthcare, Higher Education and Not-for-Profit quarterly webcast series covers FASB standard setting developments that have occurred since our May webcast. Watch as we highlight the implications of these changes and update you on any other significant developments that may occur in the interim.
Please watch this discussion on the findings of our newly released 2013 Health and Well-being Touchstone Survey. We share summary data on medical and prescription drug plan design, costs, COBRA rates, wellness and disease management programs, work-life programs, fringe benefits, future healthcare strategies, retirement benefits, and health reform.
The Obama Administration has announced that there will be an additional year before the mandatory employer and insurer reporting requirements under the Affordable Care Act (ACA) begin, and, accordingly, a one-year delay in enforcement of the employer mandate until 2015.
PwC is pleased to announce the availability of our 2013 Health and Well-being Touchstone Survey. The 2013 survey data contains detailed benefits information provided by approximately 1,100 participating companies in 35 different industries across the nation.
The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.
Merger and acquisition deal value in the pharmaceutical and life sciences sector increased in the first quarter of 2013 relative to the first quarter of 2012. The pharmaceutical segment recorded the largest gains in deal value during the quarter on the strength of several large transactions.
PwC recently convened several roundtables of employers in New York, Chicago, and Atlanta to discuss health coverage at this pivotal moment. This thought leadership article highlights the conversations and results of the related survey.
China recently introduced its 12th Five-Year Plan, which reinforces the government's commitment to easing ownership requirements. This 10Minutes discusses opportunities that private and foreign providers, payers, and investors can adopt to build a presence in China's growing healthcare market.
Healthcare companies have been gathering feedback from patients for years. Now, the accessibility of that feedback is influencing people’s healthcare decision making. Reporting requirements on ratings and reviews are prompting insurers and providers to look more comprehensively at the consumer experience.
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that medical device manufacturers will need to begin accounting for this tax for all sales, other than tax free sales, beginning January 1, 2013 and will need to consider the impact of this tax on their 2013 results.
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that the new tax law extends research & development tax credit and provides guidance on accounting for the retroactive reinstatement of the R&D tax credit.
HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders. In this issue of HR Innovation, we focus on HR Transaction Effectiveness, and delve into what it takes to effectively navigate the maze of critical talent-based decisions that can support deal success, shorten the time to close, and boost value.
On August 22, 2012 the SEC issued a final rule on conflict minerals pursuant to Dodd-Frank Section 1502. Join us as PwC panelists from our Health Industries practice lead a discussion addressing the rule, what life sciences products are likely to be covered, and what companies should be doing now.
The Supreme Court heard arguments concerning the Affordable Care Act in March 2012 and expects to issue its decision on the constitutionality of the Affordable Care Act by the end of June 2012. If the law should be invalidated by the Supreme Court, either in whole or in part, there could be significant accounting and financial reporting implications. This PwC Pharmaceutical and Life Sciences Industry Alert focuses on the potential accounting implications of the Supreme Court decision on the Affordable Care Act.
In February 2012, the Greek government announced a debt restructuring which required holders to exchange their two-year and three-year bonds, currently scheduled to mature in December 2012 and 2013, for new non-interest bearing government bonds with longer maturities and a reduced redemption value. This edition of PwC's Pharmaceutical and Life Sciences Industry Alert discusses why pharmaceutical companies will need to evaluate the debt restructuring in order to properly assess the accounting impact of this event.
The FASB and IASB released an updated exposure draft, Revenue from Contract with Customers, on November 14, 2011, and are requesting comments by March 13, 2012. In Dataline 2011-35, we share our analysis of and insight on the overall proposal. This industry supplement to Dataline 2011-35 provides specific examples and assessments of the potential affect of the updated proposal on the pharmaceutical and life sciences industry.